Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab in Newly Diagnosed Marginal Zone Lymphoma
NCT06796998Phase 2Recruiting
- Start
- Oct 2025
- Primary completion
- Oct 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of epcoritamab in marginal zone lymphoma (MZL). Primary endpoint: Complete Response at 12 months. Started Oct 2025; status: recruiting.
02
Drugs
epcoritamab
03
Conditions
marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT06796998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06796998.